HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Sean Lee has reaffirmed a Buy rating on CASI Pharmaceuticals (NASDAQ:CASI) and increased the price target from $10 to $12.
November 15, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Sean Lee maintains a Buy rating on CASI Pharmaceuticals and raises the price target from $10 to $12.
The reaffirmation of a Buy rating and an increase in the price target typically signal a positive outlook on the company's stock, suggesting potential for price appreciation. This can lead to increased investor confidence and a possible short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100